Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PIPERACILLIN SODIUM ; TAZOBACTAM SODIUM
Hospira UK Limited
J01CR05
PIPERACILLIN SODIUM ; TAZOBACTAM SODIUM
2000/250 Milligram
Pdr for Soln Inj/Inf
Product subject to prescription which may not be renewed (A)
piperacillin and enzyme inhibitor
Not marketed
2008-09-05
Page 1 of 7 Pfleet: 2016-0021153 PACKAGE LEAFLET: INFORMATION FOR THE USER PIPERACILLIN/TAZOBACTAM 2 G/0.25 G POWDER FOR SOLUTION FOR INFUSION READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion is and what it is used for 2. What you need to know before you use Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion. 3. How to use Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion 4. Possible side effects 5. How to store Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion 6. Contents of the pack and other information 1.WHAT PIPERACILLIN/TAZOBACTAM 2 G/0.25 G POWDER FOR SOLUTION FOR INFUSION IS AND WHAT IT IS USED FOR Piperacillin belongs to the group of medicines known as “broad-spectrum penicillin antibiotics”. It can kill many kinds of bacteria. Tazobactam can prevent some resistant bacteria from surviving the effects of piperacillin. This means that when piperacillin and tazobactam are given together, more types of bacteria are killed. Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion is used in adults and adolescents to treat bacterial infections, such as those affecting the lower respiratory tract (lungs), urinary tract (kidneys and bladder), abdomen, skin or blood. Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains piperacillin (as sodium salt) equivalent to 2 g and tazobactam (as sodium salt) equivalent to 0.25 g. Each vial of Piperacillin/Tazobactam 2 g/0.25 g powder for solution for infusion contains 4.72 mmol (109 mg) of sodium. Excipients: For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Powder for solution for infusion. White to off-white powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Piperacillin/tazobactam is indicated for the treatment of the following infections in adults and children over 2 years of age (see sections 4.2 and 5.1): ADULTS AND ADOLESCENTS - Severe pneumonia including hospital-acquired and ventilator-associated pneumonia - Complicated urinary tract infections (including pyelonephritis) - Complicated intra-abdominal infections - Complicated skin and soft tissue infections (including diabetic foot infections) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Piperacillin/tazobactam may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection. CHILDREN 2-12 YEARS OF AGE - Complicated intra-abdominal infections Piperacillin/tazobactam may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Read the complete document